UK government's consultation on value-based pricing for pharmaceuticals imminent
This article was originally published in SRA
The Department of Health in the UK will this week launch for consultation its plans for value-based pricing for pharmaceuticals, it has told Regulatory Affairs Pharma's sister publication Scrip Intelligence. The consultation will touch on the government's plans for the National Institute for Clinical Excellence, which will see the health technology assessment body cede to GPs (primary care physicians) its authority to definitively recommend whether or not to make certain drugs available on the National Health Service in England and Wales.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.